Optimized AAV Vectors Targeting Cochlear Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods for treating hearing loss face challenges in effectively targeting and delivering therapeutic agents to inner hair cells in the cochlea due to physical and diffusion barriers, leading to potential cell damage and suboptimal gene transfer.
Innovation Solution
Development of optimized AAV gene therapy vectors for systemic or intrathecal delivery, specifically targeting cochlear cells using promoters like CB, CMV, or Myo7A, to facilitate transgene expression in inner hair cells, outer hair cells, and other relevant cell types within the cochlea.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If direct injection into cochlear duct is used to access hair cells, then gene delivery efficiency is improved, but endocochlear potential is disrupted causing cell damage
Solution Approach 1:
The patent uses the round window membrane as an intermediary access route to deliver gene therapy vectors to cochlear cells. This membrane serves as a natural barrier that can be safely penetrated without directly disrupting the cochlear duct's endolymph fluid or endocochlear potential, thereby mediating between the need for gene delivery and the need to preserve cochlear physiology
Solution Approach 2:
The patent replaces direct mechanical injection into the cochlear duct with a less invasive approach using the round window membrane route. This substitution avoids the mechanical disruption of the delicate cochlear environment while still enabling effective vector delivery to target cells
2Productivity
If invasive methods are used to deliver therapeutic agents to inner hair cells, then gene transfer efficiency is improved, but cell damage increases
Solution Approach 1:
The round window membrane acts as an intermediary that enables therapeutic agent delivery without direct invasion of the cochlear duct. This intermediate access point allows vectors to reach target cells through a safer route that minimizes mechanical trauma and physiological disruption
Solution Approach 2:
The patent utilizes the natural anatomical structure of the round window membrane as a pre-existing access route. By preparing and administering vectors through this predetermined pathway, the method avoids the need for invasive surgical procedures that would cause additional cell damage
3Object-affected harmful factors
If systemic delivery is used to avoid invasive procedures, then cell damage is reduced, but delivery efficiency to cochlear cells decreases
Solution Approach 1:
The round window membrane serves as a localized intermediary that bridges systemic delivery with targeted cochlear cell uptake. By injecting vectors through this membrane, the system combines the advantages of minimally invasive administration with efficient local delivery to cochlear cells, overcoming the limitations of both pure systemic and pure direct injection approaches
Data Source
AI summary
The present disclosure relates to methods of targeting specific cell types within the cochlea using optimized gene therapy vectors. In particular, the disclosure provides gene therapy vectors to specifically target cochlear cells and methods of treating hearing impairment and hearing-loss related disorders.